New hope for tough ovarian cancer? early trial launches
NCT ID NCT07462468
First seen Mar 10, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug called WSK-IM02 in 36 women whose ovarian cancer has stopped responding to platinum chemotherapy. The main goal is to check the drug's safety and find the right dose, not to cure the disease. Participants will be closely monitored for side effects and how the drug works in their bodies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.